Use this URL to cite or link to this record in EThOS:
Title: Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates
Author: Spentzou, Aggeliki
ISNI:       0000 0004 2746 0883
Awarding Body: University of London
Current Institution: University of London
Date of Award: 2012
Availability of Full Text:
Access from EThOS:
We have characterized an assay measuring CD8+ T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating specificity and reproducibility and employing a panel of HIV -1 isolates. The assay uses relatively simple autologous cell culture and enzyme-linked immunosorbent assay (ELlSA), avoids generation of T cell clones and can be performed with <2 million peripheral blood mononuclear cells. Efficient CD8+ T cell-mediated cross-clade inhibition of HIV-I replication in vitro was demonstrated in antiretroviral therapy-naive HIV -l-infected subjects with controlled viral replication in vivo but not in viremic subjects. The observed HIV-I inhibition is reversed by blockade of MHC I and physical separation of effector CD8+ and target CD4+ T cells by transwell chambers. An HIV-I vaccine candidate, consisting of adenovirus (Ad) serotype 35 vectors tested in a phase I clinical trial, induced CD8+ T cells that efficiently inhibited HIV -1. Assessment of direct antiviral T cell function by this assay provides additional information to guide vaccine design and the prioritizing of candidates for further clinical trials. 2
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available